Table 2.
Patients followed up (n=94)
Weight loss >5% (n=15) |
Minimal weight loss/gain <5% (n=62) |
Weight gain >5% (n=17) |
P-value | |
---|---|---|---|---|
Weight change over study, kg* | −6.1 (0.6) | −0.2 (0.3) | 5.3 (0.6) | <0.01 |
Weight change over study, %* | −8.9 (0.8) | −0.2 (0.4) | 7.8 (0.8) | <0.01 |
Male, n (%) | 9 (60%) | 46 (74%) | 10 (59%) | 0.34 |
Age, years† | 66 (43 to 85) | 69 (48 to 84) | 66 (46 to 77) | 0.23 |
Pack-year history‡ | 35 (21 to 51) | 40 (26 to 51) | 47 (37 to 59) | 0.32 |
Δ exacerbation frequency between baseline and follow-up* | −0.5 (−2.4 to 1.4) | −0.9 (−1.6 to 0.2) | −2.0 (−3.8 to −0.3) | 0.29 |
Δ FEV1 (L)* | −0.07 (−0.19 to 0.05) | −0.15 (−0.22 to −0.09) | −0.02 (−0.18 to 0.13) | 0.15 |
Δ FEV1 (% predicted)* | −3 (−8 to 2) | −5 (−8 to −3) | 0 (−6 to 6) | 0.13 |
Δ DLCO (% predicted)* | −2 (−7 to 2) | 0 (−2 to 3) | 9 (2 to 17) | <0.01 |
Δ RV (% predicted)* | 8 (−11 to 28) | 7 (−2 to 17) | −4 (−21 to 14) | 0.50 |
Δ blood white cell count, ×109/L* | 0.6 (−0.3 to 1.5) | 0.0 (−0.5 to 0.5) | −1.2 (−2.5 to 0.2) | 0.04 |
Δ blood neutrophils, ×109/L* | 0.6 (−0.3 to 1.5) | 0.1 (−0.4 to 0.7) | −1.0 (−2.1 to 0.2) | 0.06 |
Δ blood eosinophils, ×109/L* | −0.03 (−0.09 to 0.03) | 0.00 (−0.04 to 0.05) | 0.01 (−0.10 to 0.12) | 0.79 |
Δ CRP, mg/L* | −5 (−11 to 1) | 0 (−4 to 3) | 3 (−4 to 3) | 0.34 |
Δ sputum total cell count, ×106 cells/g* | −3.5 (−8.8 to 1.9) | 0.1 (−3.5 to 3.7) | 1.3 (−5.0 to 7.6) | 0.58 |
Δ sputum neutrophils (%)* | 10.6 (−3.5 to 24.7) | −2.7 (−12.3 to 6.9) | 11.9 (1.6 to 22.2) | 0.15 |
Δ sputum eosinophils (%)* | −4.4 (−13.0 to 4.1) | 0.4 (−0.7 to 1.5) | −5.4 (−11.1 to 0.4) | 0.02 |
Notes: Data expressed as mean (SEM) unless otherwise stated.
Mean (95% CI);
mean (range);
median (interquartile range).
Abbreviations: Δ, change between baseline and follow-up measure; CI, confidence interval; CRP, C reactive protein; DLCO, total lung carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 second; RV, residual volume; SEM, standard error of the mean.